Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) rose 3.3% during trading on Friday . The stock traded as high as $14.35 and last traded at $14.29, with a volume of 409,718 shares trading hands. The stock had previously closed at $13.84.

IRWD has been the topic of several research reports. Mizuho boosted their target price on Ironwood Pharmaceuticals from $16.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, July 15th. Wedbush restated a “neutral” rating and issued a $10.00 target price on shares of Ironwood Pharmaceuticals in a research note on Thursday. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 26th. Cowen and Company upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $16.00 in a research note on Wednesday, April 6th. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 11th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $14.50.

The firm’s market cap is $2.06 billion. The firm has a 50-day moving average price of $13.03 and a 200-day moving average price of $11.05.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, May 9th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $66 million for the quarter, compared to analyst estimates of $52.97 million. During the same period in the prior year, the business earned ($0.24) EPS. The company’s revenue for the quarter was up 128.4% on a year-over-year basis. On average, equities research analysts anticipate that Ironwood Pharmaceuticals Inc. will post ($0.58) earnings per share for the current fiscal year.

In related news, insider Halley E. Gilbert sold 20,275 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $12.19, for a total transaction of $247,152.25. Following the completion of the sale, the insider now owns 5,865 shares of the company’s stock, valued at $71,494.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence S. Olanoff sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $12.92, for a total value of $28,424.00. Following the sale, the director now directly owns 32,505 shares of the company’s stock, valued at approximately $419,964.60. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors raised its position in shares of Ironwood Pharmaceuticals by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 112,315 shares of the company’s stock valued at $1,302,000 after buying an additional 1,851 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 10.9% in the fourth quarter. ProShare Advisors LLC now owns 120,454 shares of the company’s stock valued at $1,396,000 after buying an additional 11,825 shares during the last quarter. Rhumbline Advisers raised its position in shares of Ironwood Pharmaceuticals by 11.6% in the fourth quarter. Rhumbline Advisers now owns 123,715 shares of the company’s stock valued at $1,434,000 after buying an additional 12,840 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Ironwood Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 233,338 shares of the company’s stock valued at $2,704,000 after buying an additional 3,727 shares during the last quarter. Finally, Janus Capital Management raised its position in shares of Ironwood Pharmaceuticals by 2.0% in the third quarter. Janus Capital Management now owns 15,889,356 shares of the company’s stock valued at $165,569,000 after buying an additional 309,541 shares during the last quarter.

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.